Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2022-03-07 Regulatory Filings
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Ascelia Pharma suspends clinical activities in Russia
Regulatory Filings Classification · 100% confidence The document is a short announcement dated March 7, 2022, detailing Ascelia Pharma's decision to suspend clinical activities in Russia due to the invasion of Ukraine, which impacts the timeline for their Phase 3 SPARKLE study. It contains contact information, boilerplate 'About Us' sections, and concludes with an attachment link. The content is a specific operational update related to ongoing clinical trials and geopolitical events, rather than a full financial report (10-K, IR), an earnings release (ER), or a formal board change (MANG). Since it is a specific, non-financial regulatory announcement that doesn't fit the other specific categories (like DIV, CAP, DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous official announcements. Given its brevity and nature as an update/announcement, RNS is the most appropriate classification.
2022-03-07 English
Ascelia Pharma avbryter klinisk verksamhet i Ryssland
Legal Proceedings Report Classification · 99% confidence The document is a 'PRESSMEDDELANDE' (Press Release) from Ascelia Pharma dated March 7, 2022. It announces a specific operational decision (suspending clinical activity in Russia due to the Ukraine invasion) and its impact on the timeline of the SPARKLE Phase 3 study. It includes contact information and boilerplate company/product descriptions. Crucially, at the end, it lists an attached file: '[Ascelia Pharma avbryter klinisk verksamhet i Ryssland](link_to_pdf)'. Since the document itself is short (3695 chars) and primarily serves to announce the publication of information/update, it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), rather than being the full report (like 10-K or IR). Given that this is a specific operational update that doesn't fit ER, CT, or LTR perfectly, but is clearly an announcement of information being made public, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule, as it announces the release of information/update.
2022-03-07 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 95% confidence The document is a 'Bokslutskommuniké' (Year-End Report) for the period January–December 2021. It contains comprehensive financial data, including income statements, cash flow, and key performance indicators for the full year and Q4. It also includes a detailed management review (VD-ord), business updates, and pipeline information. As it covers a full fiscal year and provides substantive financial statements and analysis, it is classified as an Interim/Quarterly Report (IR) in the context of financial reporting standards, as it serves the function of a comprehensive periodic financial report. FY 2021
2022-02-10 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FULL-YEAR REPORT 2021' and covers the period January – December 2021. It contains comprehensive financial data, including key ratios (Operating Result, Earnings Per Share, Cash Flow), CEO comments, and detailed business updates. It is a full-year financial report, which falls under the category of an Interim/Quarterly Report (IR) in the provided schema, as it represents a comprehensive financial report for a specific fiscal period. FY 2021
2022-02-10 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding and voting rights for a specific holder ('Fjärde AP-fonden') in the issuer ('Ascelia Pharma AB'). It explicitly shows the 'Before the transaction' and 'After the transaction' quantities of shares and voting rights, culminating in a new percentage (6.54%). This structure is characteristic of a notification regarding a change in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The presence of specific share counts and percentage thresholds confirms this classification over general regulatory filings (RNS) or director dealings (DIRS).
2021-12-21 English
Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
Board/Management Information Classification · 99% confidence The document explicitly discusses the appointment of the Nomination Committee in preparation for the Annual General Meeting (AGM) scheduled for May 5, 2022. It details the committee members, their roles, and the duties related to proposing board members and fees for the upcoming shareholders' meeting. This content is directly related to the governance and preparation for the AGM. Although it mentions the AGM, the core subject is the committee formation, which falls under general AGM preparation materials. Since the document is an announcement about the AGM preparation rather than the meeting presentation itself, the most fitting category is AGM Information (AGM-R). It is not a proxy statement (PSI) as it doesn't solicit votes, nor is it a general regulatory filing (RNS) given the specific AGM focus.
2021-11-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.